Winia Dimchae Vaccine Freezer Receives FDA Approval... Launching Sales in the US in June

Ultra-low Temperature Vaccine Storage Freezer
[Photo by Winia Dimchae]

[Asia Economy Reporter Kim Heung-soon] Winia Dimchae announced on the 24th that its ultra-low temperature freezer developed for vaccine storage has received certification from the U.S. Food and Drug Administration (FDA), marking its official entry into the U.S. market.

Winia Dimchae developed the ultra-low temperature vaccine freezer "MediBox" in January, completing domestic trademark registration, related technology patent applications, and standard certifications. This time, as the first step to target overseas markets, it also obtained U.S. FDA certification. Starting from June, Winia plans to actively sell its ultra-low temperature freezers through platforms such as Amazon in the U.S.

The MediBox can maintain an ultra-low temperature state for a certain period (3 to 4 hours) during distribution and storage using a separate battery pack. It is compact with a capacity of 90ℓ and a weight of 65 kg, and its space utilization is optimized to store vaccines for 18,000 people per freezer. Additionally, it offers temperature settings from minus 80 degrees Celsius to plus 10 degrees Celsius, allowing customized storage for all currently available vaccines, including the ultra-low temperature transport and storage required for the UK Pfizer and U.S. Moderna vaccines, as well as those stored at room temperature, according to the company.

A Winia Dimchae official stated, "The U.S. FDA approval is the result of Winia Dimchae's products and technological capabilities being recognized in the global market," adding, "We will make every effort to launch ultra-low temperature freezers that can distribute COVID-19 vaccines more safely and quickly, contributing to rapid vaccination and the formation of herd immunity."

This content was produced with the assistance of AI translation services.